Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Novel application of polypeptide Humanin

A function, polycystic ovary technology, applied in the direction of medical preparations containing active ingredients, peptide/protein components, microbial determination/inspection, etc.

Active Publication Date: 2020-07-28
饶猛 +1
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] There is no report on the role of Humanin polypeptide in the treatment of polycystic ovary syndrome

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Novel application of polypeptide Humanin
  • Novel application of polypeptide Humanin
  • Novel application of polypeptide Humanin

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0044] Example 1: Concentration of polypeptide Humanin in follicular fluid of PCOS patients and normal ovarian function population and expression in ovarian granulosa cells

[0045] Collect follicular fluid and ovarian granulosa cells from PCOS patients undergoing IVF / ICSI assisted pregnancy and from patients with non-ovarian factors receiving assisted reproductive technology (groups with normal ovarian function); they should first be approved by the ethics committee, and the patients should be fully informed and informed before collecting the samples. Sign the informed consent.

[0046] 1. Inclusion criteria for the PCOS group: ① Female, aged 22-35; ② Diagnosed with PCOS according to the Rotterdam criteria; ③ Patients with insulin resistance. Exclusion criteria: ① combined with other endocrine diseases, such as hyperthyroidism, hypothyroidism, etc.; ② combined with other ovarian diseases, such as chocolate cysts. The control group was patients who received assisted reproduct...

Embodiment 2

[0075] Example 2: Establishment of PCOS rat model and experiment on the effects of exogenous supplementary polypeptide Humanin (HNG) on oxidative stress, endocrine and ovulation status of PCOS rats

[0076] 1. Construction of PCOS rat model

[0077]Use DHEA (dehydroepiandrosterone) to establish a rat PCOS model; select 21-day-old weaned female SD rats (about 45g), inject DHEA subcutaneously, and the injection volume is 6mg / 100g body weight, and dissolve DHEA with 0.2mL injection oil , continuous injection for 20 days;

[0078] 2. Sixty 21-day-old SD rats were purchased from the Experimental Animal Center of Huazhong University of Science and Technology. The rats were randomly divided into 5 groups with 12 rats in each group. The specific groups are as follows:

[0079] A. PCOS rat model group

[0080] B. PCOS model + low dose HNG group

[0081] C. PCOS model + medium dose HNG group

[0082] D. PCOS model + high dose HNG group

[0083] E. Blank control group

[0084] The ...

Embodiment 3

[0107] Example 3: Construction of a cell model of oxidative stress injury, and the molecular mechanism experiment of polypeptide Humanin in alleviating oxidative stress 1. Identification of ovarian granulosa cell line COV434 and primary rat granulosa cells and verification experiment of Humanin expression in it

[0108] 1) Preparation of COV434 cell slides

[0109] a. Digest COV434 cells with trypsin infiltration method: Discard the medium, wash with PBS twice, add 300 μL of trypsin to the cell culture flask, completely infiltrate the cells, use a pipette to suck out the trypsin and discard it, and wait for the cells to digest into quicksand, add complete medium to stop digestion;

[0110] b. Inoculate the cells in a 24-well culture dish containing cell slides, and culture them in an incubator until the cells grow to the required experimental density;

[0111] 2) Extraction of primary rat granulosa cells and preparation of cell slides

[0112] a. 26-day-old SD rats were intr...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a novel application of polypeptide Humanin, namely an application of a polypeptide Humanin gene as an action target in screening and preparing a medicine for treating polycystic ovarian syndrome, or an application of polypeptide Humanin in preparing a medicine for treating polycystic ovarian syndrome. Experimental results show that the exogenous supplementation of Humanin polypeptide can obviously reduce the weight of a PCOS rat, reduce the androgen level of the PCOS rat, improve the ovulation state and reduce the systematic and partial oxidative stress level of the PCOS rat; the exogenous supplementation of Humanin polypeptide can obviously reduce fasting blood glucose and fasting insulin levels of the PCOS rat, and reverse abnormal conduction of a glycometabolismpathway IRS1 / PI3K / AKT and abnormal protein expression of GLUT4 in ovarian granular cells of the PCOS rat; the polypeptide Humanin gene provides possibility for developing polycystic ovarian syndrome drugs based on the polypeptide Humanin gene in the future, and the invention has great application value and prospect.

Description

technical field [0001] The present invention relates to a new application of polypeptide Humanin, that is, its application in treating polycystic ovary syndrome. Background technique [0002] Polycystic ovary syndrome (PCOS) is a common syndrome of endocrine and metabolic abnormalities in women of reproductive age, characterized by chronic oligoovulation, anovulation, and hyperandrogenism, often accompanied by insulin resistance and Abnormal metabolism, clinical manifestations are irregular menstrual cycle, hirsutism, acne, infertility, etc.; the incidence rate is 5%-15%, and it accounts for about 75% in ovulation disorder infertility patients. [0003] The pathogenesis of polycystic ovary syndrome is complex and still not fully understood. Accumulating evidence shows that systemic and local chronic inflammation, imbalance of oxidative stress are associated with polycystic ovary syndrome and its metabolic abnormalities. Chronic inflammation interacts with oxidative stress ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12Q1/6883A61K38/17A61P15/08
CPCC12Q1/6883A61K38/1709A61P15/08C12Q2600/106
Inventor 饶猛王莹莹
Owner 饶猛
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com